Abstract Number: 3124 • 2015 ACR/ARHP Annual Meeting
Associations of Circulating Cell-Free Micro-RNA with Vasculopathy and Vascular Events in SLE Patients
Background/Purpose: MicroRNAs (miRNAs) are small noncoding RNAs that modulate protein translation and regulate numerous immunologic and inflammatory pathways. Certain miRNA profiles have been associated with…Abstract Number: 2003 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Is Characterized By Endothelial Progenitor Dysfunction and a Type I Interferon Signature
Background/Purpose: Patients with primary antiphospholipid syndrome (APS) are at risk for endothelial dysfunction and accelerated atherosclerosis. In systemic lupus erythematosus (SLE), there is a well-established…Abstract Number: 2005 • 2015 ACR/ARHP Annual Meeting
Circulating Mirnas As Potential Disease Biomarkers in Antiphospholipid Syndrome Patients
Background/Purpose: Epigenetic anomalies are emerging as striking pathogenic features of autoimmune disorders. MicroRNAs (miRNAs) are small non-coding RNAs with a key role in regulatory networks that…Abstract Number: 2174 • 2015 ACR/ARHP Annual Meeting
Neutrophils in Primary Antiphospholipid Syndrome Are Characterized By a Prominent Activated Phenotype and Uniquely Remodeled Chromatin Architecture
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by recurrent thrombotic events, pregnancy complications, and the presence of antiphospholipid antibodies. The pathogenesis of…Abstract Number: 2175 • 2015 ACR/ARHP Annual Meeting
Comparative Study Between Coagucheck XS Versus Standard Laboratory Practice Protrombine Time for Monitoring Anticoagulant Therapy in Patients with Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune disease characterized by antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although initially described in patients with systemic lupus erythematosus (SLE) it…Abstract Number: 2178 • 2015 ACR/ARHP Annual Meeting
Oxidation of beta2-Glycoprotein I (beta2-GPI) Associates with the Presence of Antibodies to Domain I of beta2-GPI in Patients with the Antiphospholipid Syndrome but Is Not Affected By the Antibodies in Vivo in a Rat Model
Background/Purpose: β2GPI represents the major antigenic target for antiphospholipid antibodies (aPL), the hallmark of antiphospholipid syndrome (APS). β2GPI contains five homologous domains, with domain I…Abstract Number: 2180 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients display high levels of the cell-bound complement activation factor C4d deposits on erythrocytes, B lymphocytes and platelets. In particular,…Abstract Number: 2183 • 2015 ACR/ARHP Annual Meeting
Clinical and Epidemiological Correlates of the Adjusted Global Anti-Phospholipid Syndrome Score in a Large Cohort of Chinese APS Patients
Background/Purpose: It is well known that anti-phospholipid antibodies (aPL) are associated with an increased risk of arterial and venous thrombosis and pregnancy loss/morbidity. However, anticoagulation…Abstract Number: 2184 • 2015 ACR/ARHP Annual Meeting
Non-Criteria Clinical Manifestations in Antiphospholipid Syndrome: Clinical Behavior and Association with Damage Accrual
Background/Purpose: The relevance of non-criteria clinical manifestations of antiphospholipid syndrome (APS) has been less studied than its thrombotic and obstetric features. The aim of this…Abstract Number: 2186 • 2015 ACR/ARHP Annual Meeting
The Role of Hydroxychloroquine Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies
Background/Purpose: With good management, around 70% of pregnant women with Antiphospholipid Syndrome (APS) will deliver a viable live infant.However, current management does not prevent all…Abstract Number: 2192 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Thrombocytopenia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose : Thrombocytopenia is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our objective was…Abstract Number: 7 • 2014 ACR/ARHP Annual Meeting
Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients
Background/Purpose To investigate the beneficial effects of in vivoubiquinol (Q) supplementation on athero-thrombosis prevention in APS patients. Methods The study was performed on 10 APS…Abstract Number: 5 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid-Associated Nephropathy Is a Risk for Developing Arterial Thromboses in Patients with Systemic Lupus Erythematosus
Background/Purpose: Antiphospholipid-associated nephropathy (APLN) is characterized by coexistence of antiphospholipid antibodies (aPLs) and renal small-vessel vasculopathy/chronic renal ischemia. Consequences of APLN to thrombosis have yet…Abstract Number: 4 • 2014 ACR/ARHP Annual Meeting
Detection of Anti-Beta2glycoprotein I Domain 1 Antibodies By an Automated Chemiluminescence Assay in a Cohort of 400 Clinically Characterized Consecutive Routine Samples
Background/Purpose: Several studies suggested that antibodies to Domain 1 of beta2glycoprotein I (a-B2GPI-D1) represent a promising biomarker for the diagnosis and risk assessment of Antiphospholipid…Abstract Number: 16 • 2014 ACR/ARHP Annual Meeting
Differential Assay Reactivity of IgA Anti-B2glycoprotein I Antibodies: Implications for Clinical Interpretation of Antiphospholipid Antibody Testing
Background/Purpose: IgA anti-β2Glycoprotein I (aβ2GPI) antibodies remain controversial in the assessment of thrombotic risk in spite of several studies indicating an association with thromboembolic…
ACR Meeting Abstracts